HK1148435A1 - Oxadiazoanthracene compounds for the treatment of diabetes - Google Patents

Oxadiazoanthracene compounds for the treatment of diabetes

Info

Publication number
HK1148435A1
HK1148435A1 HK11102525.7A HK11102525A HK1148435A1 HK 1148435 A1 HK1148435 A1 HK 1148435A1 HK 11102525 A HK11102525 A HK 11102525A HK 1148435 A1 HK1148435 A1 HK 1148435A1
Authority
HK
Hong Kong
Prior art keywords
oxadiazoanthracene
diabetes
compounds
treatment
oxadiazoanthracene compounds
Prior art date
Application number
HK11102525.7A
Other languages
English (en)
Chinese (zh)
Inventor
‧米加裡
‧波裡塞蒂
‧約庫姆
‧桑托什
‧居澤爾
‧貝梅
‧戴維斯
Original Assignee
轉化技術製藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 轉化技術製藥有限責任公司 filed Critical 轉化技術製藥有限責任公司
Publication of HK1148435A1 publication Critical patent/HK1148435A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK11102525.7A 2008-03-07 2011-03-14 Oxadiazoanthracene compounds for the treatment of diabetes HK1148435A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Publications (1)

Publication Number Publication Date
HK1148435A1 true HK1148435A1 (en) 2011-09-09

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102525.7A HK1148435A1 (en) 2008-03-07 2011-03-14 Oxadiazoanthracene compounds for the treatment of diabetes

Country Status (18)

Country Link
US (7) US7727983B2 (ru)
EP (1) EP2262364B1 (ru)
JP (1) JP5382952B2 (ru)
KR (1) KR101616737B1 (ru)
CN (1) CN101959405B (ru)
AU (1) AU2009221722B2 (ru)
BR (1) BRPI0910282A2 (ru)
CA (1) CA2716664C (ru)
DK (1) DK2262364T3 (ru)
EA (1) EA018225B1 (ru)
ES (1) ES2567451T3 (ru)
HK (1) HK1148435A1 (ru)
IL (1) IL207570A (ru)
MA (1) MA32175B1 (ru)
MX (1) MX2010009752A (ru)
NZ (1) NZ587343A (ru)
WO (1) WO2009111700A2 (ru)
ZA (1) ZA201006367B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
EA023430B1 (ru) * 2009-03-30 2016-06-30 виТиви ТЕРАПЬЮТИКС ЭлЭлСи Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
WO2012096824A1 (en) * 2011-01-12 2012-07-19 Transtech Pharma, Inc. Phenylglyoxylic acid derivatives and their preparation and use
CA2825102C (en) 2011-02-08 2016-03-08 Pfizer Inc. Glucagon receptor modulators
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EA201491749A1 (ru) * 2012-03-22 2015-01-30 ТРАНСТЕК ФАРМА, ЭлЭлСи Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
CN104968341B (zh) 2013-01-17 2020-06-09 Vtv治疗有限责任公司 Glp1r激动剂和二甲双胍的组合及其在制备治疗2型糖尿病和其他障碍的药物中的用途
CN107074820B (zh) * 2014-07-25 2021-05-18 赛尔基因第二国际有限公司 Glp-1受体调节剂
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
KR20210005843A (ko) 2018-05-08 2021-01-15 브이티브이 테라퓨틱스 엘엘씨 Glp1r 작용제의 치료적 용도
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN115667268A (zh) * 2020-05-28 2023-01-31 杭州中美华东制药有限公司 一种glp-1受体激动剂游离碱的制备方法
EP4159719A1 (en) * 2020-05-28 2023-04-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
US20230322756A1 (en) 2020-09-01 2023-10-12 Jiangsu Hengrui Medicine Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
EP4227299A1 (en) 2020-10-12 2023-08-16 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
EP4242202A4 (en) 2020-11-27 2024-05-15 Shenzhen Salubris Pharm Co Ltd BENZIMIDAZOLE DERIVATIVE, ITS PREPARATION METHOD AND ITS MEDICAL USE
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
EP4317145A1 (en) 2021-03-24 2024-02-07 Shionogi & Co., Ltd Pharmaceutical composition containing glp-1 receptor agonist having fused ring
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CN117098758A (zh) 2021-06-24 2023-11-21 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233728A1 (en) 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物
KR100625255B1 (ko) * 1995-10-06 2008-01-30 리간드 파마슈티칼스 인코포레이티드 다이머-선택적rxr변조물질및그의사용방법
AU3033500A (en) * 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
MXPA02005528A (es) * 1999-12-03 2002-09-02 Kyoto Pharma Ind Compuestos heterociclicos sus sales y uso medicinal.
EP1125925A1 (en) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
MXPA05010137A (es) * 2003-03-26 2005-11-16 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
EA018225B1 (ru) * 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のｇｌｐ−１受容体安定化薬および調節薬

Also Published As

Publication number Publication date
US20130317015A1 (en) 2013-11-28
IL207570A (en) 2014-03-31
CA2716664A1 (en) 2009-09-11
BRPI0910282A2 (pt) 2015-09-01
US20150087640A1 (en) 2015-03-26
AU2009221722B2 (en) 2014-12-18
DK2262364T3 (en) 2016-03-21
US20090306063A1 (en) 2009-12-10
CN101959405A (zh) 2011-01-26
WO2009111700A3 (en) 2010-03-04
IL207570A0 (en) 2010-12-30
WO2009111700A2 (en) 2009-09-11
JP5382952B2 (ja) 2014-01-08
MX2010009752A (es) 2010-09-30
AU2009221722A1 (en) 2009-09-11
US20140187769A1 (en) 2014-07-03
US20110039837A1 (en) 2011-02-17
US8524708B2 (en) 2013-09-03
CN101959405B (zh) 2014-07-02
ZA201006367B (en) 2011-05-25
ES2567451T3 (es) 2016-04-22
EA018225B1 (ru) 2013-06-28
KR20100131455A (ko) 2010-12-15
US7727983B2 (en) 2010-06-01
KR101616737B1 (ko) 2016-05-02
JP2011513431A (ja) 2011-04-28
US7906507B2 (en) 2011-03-15
EP2262364A4 (en) 2012-04-04
EP2262364A2 (en) 2010-12-22
US20100324033A1 (en) 2010-12-23
NZ587343A (en) 2012-05-25
US20100197677A1 (en) 2010-08-05
MA32175B1 (fr) 2011-03-01
US8933222B2 (en) 2015-01-13
US8703766B2 (en) 2014-04-22
EP2262364B1 (en) 2016-03-02
EA201071045A1 (ru) 2011-02-28
US9120813B2 (en) 2015-09-01
CA2716664C (en) 2016-10-11
US7790714B2 (en) 2010-09-07

Similar Documents

Publication Publication Date Title
HK1148435A1 (en) Oxadiazoanthracene compounds for the treatment of diabetes
IL259475A (en) Combined therapy for the treatment of diabetes
ZA200902374B (en) Compositions useful for the treatment of diabetes
ZA201105720B (en) Compounds for the treatment of hepatitis c
HUE043569T2 (hu) Vegyületek rák kezelésére
EP2320907A4 (en) THERAPEUTIC COMPOUNDS
ZA200906129B (en) Compounds for the treatment of hepatitis c
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2268285A4 (en) THERAPEUTIC COMPOUNDS
GB0806794D0 (en) Therapeutic compounds
SI2209784T1 (sl) Spojine za zdravljenje hepatitisa C
ZA201000923B (en) Compounds for the treatment of hepatitis c
GB0813740D0 (en) Therapeutic compounds
GB0804755D0 (en) Therapeutic compounds
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
EP2358200A4 (en) BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
IL211267A0 (en) Oxadiazole derivatives for the treatment of diabetes
EP2331099A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS
GB0819536D0 (en) Compounds for the treatment of neoplasia
GB0817857D0 (en) Compounds for the treatment of neoplasia
GB0802903D0 (en) Treatment of diabetes
GB0814997D0 (en) Processes for the preparation of compounds
GB0809319D0 (en) The treatment of puritus
GB0821817D0 (en) Therapeutic compounds
GB0815700D0 (en) Therapeutic compounds